➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
Moodys
Johnson and Johnson
Medtronic
Boehringer Ingelheim

Last Updated: September 27, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ACYCLOVIR; HYDROCORTISONE

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for ACYCLOVIR; HYDROCORTISONE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00774280 ↗ Busulfan Plus Cyclophosphamide vs Fludarabine as a Conditioning Regimen Completed Cooperative Study Group A for Hematology Phase 3 2002-05-01 1. At the same time of registration, patients will be randomized to one of the two conditioning therapy groups; Arm I (intravenous busulfan plus cyclophosphamide; BuCy) or Arm II (intravenous busulfan plus fludarabine; BuFlu). 2. Randomization will be a stratified permuted-block design. 2.1The patients will be stratified into standard risk vs. high risk group, and related vs. unrelated donor. Standard risk group will be defined as follows: patients with acute leukemia in first remission, CML in chronic phase, and MDS (RA or RARS categories). High risk group will be defined as follows: patients with acute leukemia in relapse or in second or subsequent remission, CML in accelerated or blastic phase, and MDS (CMMoL or RAEB categories). 2.2.Pre-assigned block size is 8.
NCT01574612 ↗ Open Label Safety Study of Xerese Cream in the Treatment of Recurrent Herpes Labialis in Children 6-11 Years Old Completed TKL Research, Inc. Phase 3 2012-03-01 To test the safety of Xerese (acyclovir and hydrocortisone)Cream 5%/1% for the treatment of recurrent cold sores in children ages 6-11yrs after 5 days of treatment.
NCT01574612 ↗ Open Label Safety Study of Xerese Cream in the Treatment of Recurrent Herpes Labialis in Children 6-11 Years Old Completed Meda Pharmaceuticals Phase 3 2012-03-01 To test the safety of Xerese (acyclovir and hydrocortisone)Cream 5%/1% for the treatment of recurrent cold sores in children ages 6-11yrs after 5 days of treatment.
NCT03299452 ↗ Clinical Studies by Using Accelerated PDX Model to Screen Drugs for Advanced Solid Tumor Recruiting Haining Health-Coming Biotech Co., Ltd. Phase 2 2017-01-01 This is a single-center, open-label, single-arm, non-randomized study designed to evaluate PFS,safety, overall survival (OS), objective response rate (OPR), disease control rate (DCR) and biomarkers of cancer therapy based on the accelerated PDX model screening in subjects with advanced malignant tumor.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for ACYCLOVIR; HYDROCORTISONE

Condition Name

Condition Name for ACYCLOVIR; HYDROCORTISONE
Intervention Trials
Metastatic Cancer 1
Leukemia 1
Herpes Labialis 1
Myelodysplastic Syndrome 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for ACYCLOVIR; HYDROCORTISONE
Intervention Trials
Neoplasm Metastasis 1
Herpes Labialis 1
Syndrome 1
Preleukemia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for ACYCLOVIR; HYDROCORTISONE

Trials by Country

Trials by Country for ACYCLOVIR; HYDROCORTISONE
Location Trials
United States 9
China 1
Korea, Republic of 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for ACYCLOVIR; HYDROCORTISONE
Location Trials
Virginia 1
Texas 1
Rhode Island 1
North Carolina 1
New York 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for ACYCLOVIR; HYDROCORTISONE

Clinical Trial Phase

Clinical Trial Phase for ACYCLOVIR; HYDROCORTISONE
Clinical Trial Phase Trials
Phase 3 2
Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for ACYCLOVIR; HYDROCORTISONE
Clinical Trial Phase Trials
Completed 2
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for ACYCLOVIR; HYDROCORTISONE

Sponsor Name

Sponsor Name for ACYCLOVIR; HYDROCORTISONE
Sponsor Trials
Haining Health-Coming Biotech Co., Ltd. 1
Meda Pharmaceuticals 1
TKL Research, Inc. 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for ACYCLOVIR; HYDROCORTISONE
Sponsor Trials
Industry 2
Other 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
Express Scripts
McKinsey
Merck
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.